ArticleScientific reports2026
Wogonin attenuates psoriasis through anti-inflammatory effects by inhibiting reactive oxygen species production and the AKT/NF-κB signaling pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tempol Ameliorates Psoriatic Skin Inflammation: Evidence of TLR4/NF-κB/Nrf2 Axis Modulation.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Psoriasis is a common, chronic, inflammatory skin disease that affects many patients and exerts a heavy physical and mental burden. Wogonin (WG), derived from the root extract of Scutellaria Baicalensis, has shown therapeutic effects in a variety of inflammatory diseases. However, its specific effects and mechanisms in psoriasis treatment remain poorly understood. This study aimed to investigate the therapeutic effects and underlying mechanisms of WG in psoriasis. In this study, we first identified potential therapeutic targets of WG for psoriasis by intersecting the corresponding targets of psoriasis and WG, then performed Protein-Protein Interaction (PPI) network analysis and enrichment analyses. Next, we employed Cytoscape to identify potential key targets and performed molecular docking to predict possible targets. M5-induced HaCaT cells and imiquimod (IMQ)-mouse models were used to explore the effects and mechanisms. Bioinformatic analyses indicated that WG may exert anti-inflammatory effects through inhibiting PI3K/AKT pathway activation and oxidative stress. In vitro results showed that WG suppressed the increase of pro-inflammatory cytokine expression levels, reactive oxygen species (ROS) level, phosphorylation of Akt and p65, and several key target mRNA expression levels induced by M5 stimulation. Oral administration of WG remarkably alleviated psoriatic like lesions in IMQ-induced mice, inhibited inflammatory cytokines and Ki-67 expression level in mouse skin lesions. Our results indicate that WG exhibits significant anti-inflammatory effects in psoriasis by suppressing reactive oxygen species (ROS) production and inhibiting the AKT/NF-κB signaling pathway. These results highlight WG's potential as a promising therapeutic agent for psoriasis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.